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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of rapid susceptibility testing versus standard susceptibility testing for bloodstream infections (BSIs).
B A C K G R O U N D
Description of the condition
Bloodstream infections (BSIs) can be defined as the presence of
viable bacteria or fungi in the blood that is associated with in-
fection (Laupland 2014). Blood culture is the reference standard
for detection of these micro-organisms in blood (Baron 2013).
BSIs may be categorized as primary infections, defined as those
not secondary to an infection at another body site, and secondary
infections, where organisms are seeded from a site-specific infec-
tion at another body site, for example a pneumonia. In primary
BSIs, organisms may enter the bloodstream through broken skin
or mucous membranes, gastrointestinal tract or by the direct in-
troduction of contaminated material to the bloodstream (Reimer
1997).
Positive blood cultures may not always signify BSI, and may rep-
resent contamination or the transient presence of bacteria in the
blood that do not cause clinical illness. Similarly, BSI may not
always lead to sepsis.
Incidence estimates for BSI vary from 166 to 204 episodes per
100,000 person-years in North America and Europe (Goto 2013).
BSI is also common in Africa, with a prevalence of 7.4% (4.2%
to 16.9%) among all admissions irrespective of fever history, with
higher risk in the immunocompromised (Reddy 2010).
BSIs are often associated with and, less frequently, may cause sep-
sis, defined as life-threatening organ dysfunction due to a dysreg-
ulated host response to infection (Rhodes 2017). Given the com-
plex nature of the condition and its diagnosis, it is impossible to
give precise estimates for the global burden of disease from sepsis.
However, the World Health Organization (WHO) estimates that
there are up to 31 million and 24 million global cases of sepsis and
1Rapid versus standard antibiotic susceptibility testing for treating bloodstream infections (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
septic shock, respectively, with the clinical conditions resulting in
sepsis accounting for up to six million deaths (WHO 2017).
Observational studies indicate that inappropriate empirical an-
timicrobials and delays in the initiation of appropriate antibiotic
therapy are risk factors for mortality in sepsis, with a progressive
increase in mortality with increasing delays (Ferrer 2014; Kumar
2006; Kumar 2009; Paul 2010). By necessity, the evidence for the
antibiotic treatment of sepsis is observational, as randomized con-
trolled trials (RCTs) would be unethical. Notwithstanding, sep-
sis guidelines emphasize early broad-spectrum antimicrobial treat-
ment aimed at ensuring adequate therapy to reduce mortality.
Such use of early broad-spectrum antimicrobials has led to con-
cerns that patients are exposed to overuse of antimicrobials, which
may result in antimicrobial resistance (Silva 2013). As such, guide-
lines recommend that antimicrobial therapy is targeted to a specific
pathogen, if this is identified microbiologically (Rhodes 2017).
The use of targeted therapy is regarded as an important compo-
nent of antimicrobial stewardship, defined as a set of actions that
promote using antimicrobials responsibly (Dyar 2017).
Description of the intervention
The parallel global drives to improve both the treatment of se-
vere infections associated with BSI and to avoid antimicrobial re-
sistance have catalyzed new strategies to reduce the turn-around
time between the collection of blood culture samples frompatients
and the reporting of antimicrobial susceptibility results. Proported
benefits of reduced turn-around times include reduced morbid-
ity and mortality, improved patient care, reduced healthcare costs,
and reduced antimicrobial resistance (PHE 2014).
Figure 1 depicts an overview of the laboratory diagnosis and clin-
ical management of BSI. A clinician collects a blood culture from
a patient with possible BSI, and may commence empirical an-
tibiotics. The clinician sends this to the microbiology laboratory.
Upon receipt, the laboratory staff load the blood cultures into
an incubation machine. Different blood culture systems then use
a variety of methods to detect micro-organisms, and the culture
bottles will ‘flag positive’ if detected. The term ‘time to positivity’
is the time between which the clinician collects the culture, and
the time at which the culture ‘flags positive’. Time to positivity is
typically 12 to 24 hours.
Figure 1. Time to appropriate antibiotics: time to first appropriate antibiotic (from collection time of
positive blood culture to start of an antibiotic which has in vitro activity versus the identified organism)
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After the blood culture ‘flags positive’, laboratory staff remove the
blood culture from the machine, and perform a Gram stain and
microscopy. Laboratory staff then perform subcultures to isolate
one or more organisms, and use either conventional culture meth-
ods or rapid testing to report organism identification and antimi-
crobial susceptibility. Using conventional methods, this period is
typically a further 36 hours (Maurer 2017). The clinician is then
required to act upon this report, and change or continue antibi-
otics appropriately. The term ‘time to appropriate antibiotic’ is
the time between which the clinician collects the culture, and the
time at which targeted antibiotics are prescribed according to the
susceptibility result.
The advent of mass spectrometry over the past decade has allowed
great reductions in the time to identification (Doern 2018). How-
ever, a reduction in time from a blood culture flagging positive
and antimicrobial susceptibility results being available, is a more
elusive target.
In recent years, novel rapid antimicrobial susceptibility tests are
emerging. These can be grouped into the following two main
categories (Maurer 2017).
• Genotypic or molecular antimicrobial susceptibility testing:
this form of testing identifies the presence or absence of a
resistance gene or its product. It can indicate which
antimicrobials the organism is unlikely to be susceptible to.
• Rapid phenotypic antimicrobial susceptibility testing: this
describes detection of growth in the presence of an antibiotic.
For the purpose of this review, the term ‘rapid’ includes those that
produce susceptibility results in≤ 8 hours from the time the blood
culture flags positive. This definition relates to the laboratory work
day, in which batch testing is performed one or more times per 8-
hour working shift (Buehler 2015).
How the intervention might work
Rapid antimicrobial susceptibility tests are expected to reduce
the time to clinically important results of a blood culture. This
might allow clinicians to better target therapy to patients’ needs,
and thereby both improve patient outcomes (mortality, morbid-
ity, length of hospital stay), and reduce unnecessary prescribing of
broad-spectrum antibiotics and so reduce antimicrobial resistance
rates.
Why it is important to do this review
Rapid susceptibility testing offers a theoretical benefit to patient
outcomes, with reduced time to targeted antibiotic therapy and,
as such, potential reduced morbidity and mortality. It also offers
theoretical benefit to improve antimicrobial stewardship and, as
such, reduce antimicrobial resistance, which is a key concern glob-
ally. Notwithstanding the theoretical benefits, there is limited cer-
tainty in the evidence. This Cochrane Review may help improve
certainty regarding potential benefits of this emerging technology
to patient outcomes and stewardship outcomes. As such, the re-
view may guide clinicians and laboratories in the effective imple-
mentation of rapid susceptibility testing, and appropriate resource
allocation to the technology.
O B J E C T I V E S
To assess the effects of rapid susceptibility testing versus standard
susceptibility testing for bloodstream infections (BSIs).
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs).
Types of participants
People of any age with a BSI caused by any bacteria, as identified
by a positive blood culture and clinical signs of infection.
Types of interventions
Experimental intervention
Rapid antimicrobial susceptibility testing, defined as an in vitro
laboratory test to determine if an antimicrobial agent will be ac-
tive in inhibiting the growth of an organism, performed directly
from a positive blood culture bottle, with a time-to-result of ≤ 8
hours from the blood culture flagging positive. These may include
molecular antimicrobial susceptibility tests or phenotypic antimi-
crobial susceptibility tests, using the definitions given above, and
may include other methods not incorporated by these definitions,
if they are identified by our search. Appendix 1 lists interventions
that may meet these criteria.
Comparator
Conventional routine standard antimicrobial susceptibility tech-
niques (automated systems, broth microdilution, manual suscep-
tibilities, disc diffusion or E-tests).
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Types of outcome measures
Primary outcomes
• Mortality (all-cause 30-day mortality, after date of positive
blood culture)
• Time to discharge from hospital after positive blood culture
in days
Secondary outcomes
Time from empirical antibiotic prescription to targeted or defini-
tive therapy; to include the following.
• Time to patient receipt of an antibiotic with in vitro activity
versus the identified organism
• Time to de-escalation: switching from a broad- to a narrow-
spectrum antibiotic or discontinuation of one or more antibiotics
• Time to escalation: switching from a narrow- to a broad-
spectrum antibiotic or initiation of one or more antibiotics
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, on-
going).
Electronic searches
We will search the following databases using the search terms
and strategy described in Appendix 2: Cochrane Infectious
Diseases Group Specialized Register; Central Register of Con-
trolled Trials (CENTRAL), published in the Cochrane Library;
MEDLINE (PubMed); and LILACS. We will also search the
WHO International Clinical Trials Registry Platform (ICTRP;
www.who.int/ictrp), and ClinicalTrials.gov (clinicaltrials.gov), for
trials in progress, using “bloodstream infection*” and “antimicro-
bial susceptibility tests” as search terms.
Searching other resources
Reference lists
We will also check the reference lists of all studies identified by the
above methods and of previously published reviews, and we will
use the “similar articles” function in PubMed to identify related
data.
Researchers and organizations
In addition to the electronic searches described above, we will
contact researchers in the field to identify additional published
and unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (VA and PH) will independently screen ref-
erences by title and abstract according to our inclusion criteria.
We will exclude studies that do not report on our primary or sec-
ondary outcomes. We will include studies that assess a single resis-
tance trait. We will resolve any disagreement through discussion;
if unable to reach agreement we will discuss with a third review
author (TP or SK).Wewill obtain and assess the full-text of poten-
tially eligible articles. We will list studies we exclude after full-text
screening and their reasons for exclusion in a ‘Characteristics of
excluded studies’ table. We will present a PRISMA flow diagram
(Moher 2009).
Data extraction and management
Two review authors (VA and PH) will independently extract data
using a piloted, tailored data extraction form. We will resolve any
disagreement by discussion or through a third review author (TP).
For dichotomous outcomes (mortality), we will extract the num-
ber of events in each arm of the included RCTs. For all other out-
comes, which are time-to-event outcomes, we will extract the log
hazard ratio and its standard error from Cox proportional hazards
models. If trial authors do not report standard errors, we will ex-
tract the hazard ratio with its confidence interval (CI) or P value,
or both, and use these to obtain estimates of standard error. If
trials analyse time-to-event data with models other than a Cox
proportional hazards model, we will collect the relevant data for
methods of meta-analysis of time-to-event outcomes as described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
Assessment of risk of bias in included studies
Two review authors (VA and PH) will independently assess risk
of bias using the Cochrane ‘Risk of bias’ tool (Higgins 2011), and
where necessary, contacting trial authors for further information.
We will resolve any disagreement via discussion. In the event that
a disagreement cannot be resolved, a third review author (TP) will
make the final decision. We will record the rationale used to deter-
mine the risk of bias in each of the six domains for each included
study. The six domains include: selection bias, performance bias,
detection bias, attrition bias, reporting bias and other bias. We will
make a final decision on each study’s level of bias based on this.
Measures of treatment effect
For mortality, a dichotomous outcome, we will present risk ra-
tio (RR), comparing rapid susceptibility testing to conventional
methods with respective 95% CIs.
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For all other outcomes, which are time-to-event outcomes (time
to discharge from hospital, time to first appropriate escalation/
de-escalation, time to first appropriate antibiotic), we will present
hazard ratios (HRs) with respective 95% CIs.
Unit of analysis issues
When a trial with more than two arms contributes multiple com-
parisons to a particular meta-analysis, we will combine treatment
groups or split the ‘shared’ group to avoid double-counting.
If we encounter cluster-RCTs that did not adjust results for cluster
design, we will adjust the sample sizes using an estimate of the
intracluster correlation coefficient (ICC) before including data
from these studies in our meta-analysis. If the ICC is not available,
we will use an ICC from another, similar study.
Dealing with missing data
We will assess missing data to ascertain whether it may be related
to the outcomes. If missing data restricts the use of the study in
quantitative synthesis, we will contact trial authors for clarification
or to provide further information. If data are missing at random,
we will analyse only available cases. If the amount of incomplete
outcome data is such that the trial is thought to be at a high risk
of bias, we may use imputation and perform sensitivity analyses
to investigate the impact of this missing data.
Assessment of heterogeneity
We will visually inspect the forest plots for overlapping CIs as an
indicator of heterogeneity.We will also assess the Chi2 and I2 tests
of heterogeneity. For the purposes of this review, an I2 statistic value
> 75% will indicate considerable heterogeneity. However we will
not consider this as a simple ‘threshold’, but instead interpret this
in the context of the size and direction of events, the Chi2 P value,
and possible causes. Where heterogeneity remains considerable,
we will not perform meta-analysis.
Assessment of reporting biases
We will create funnel plots to assess reporting bias if more than 10
studies contribute to an outcome in meta-analysis, and examine
this for asymmetry.
Data synthesis
We will meta-analyse data using Review Manager 5 (Review
Manager 2014).We anticipate that wewill find heterogenous pop-
ulations and interventions, so we therefore plan to use a random-
effects model for meta-analysis for both dichotomous and time-
to-event data.
In addition to quantitative synthesis using meta-analysis, we will
perform planned qualitative (narrative) synthesis based on formal
guidance. If we are unable to meta-analyse due to heterogeneity
in outcome measures, to develop a preliminary synthesis we will
use textual descriptions of studies, groupings and clusters, and
tabulation (Popay 2006).
We will also perform qualitative synthesis to explore the relation-
ships between data by examining moderating variables that may
explain findings at study level, developing conceptual models, and
giving qualitative case descriptions where rapid susceptibility test-
ing has been particularly effective or ineffective.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analysis of instances where rapid sus-
ceptibility testing is introduced alone, and where it is introduced
as a multicomponent intervention, for example, including other
elements of antimicrobial stewardship. If our search indicates that
rapid susceptibility testing is being introduced within different
settings, we may investigate the effect of this. We recognise that
there may be heterogeneity in our antimicrobial stewardship out-
comes, as the concept of ‘targeting’ antibiotics, and of escalation or
de-escalation, are by nature subjective. If we encounter different
methods of defining these outcomes, we will explore this using
subgroup analysis.
Sensitivity analysis
We will perform a worst-case scenario analysis by imputing the
missing data as poor outcomes in the rapid susceptibility group
and good outcomes in the control group, and by comparing this
to our available case analysis to explore the effect of missing data
on our primary outcomes.
If we identify high risk of bias for some trials, we will perform
sensitivity analysis by assessing results after excluding these trials.
Where we are required to estimate ICCs or borrow ICCs from
other studies for cluster-RCTs, we will conduct sensitivity analyses
to investigate the impact of these assumptions.
Certainty of the evidence
We will summarize our findings in a ‘Summary of findings’ ta-
ble. We will present the following primary and secondary out-
comes: all-cause 30-day mortality after date of positive blood cul-
ture, time to discharge from hospital after positive blood culture,
time to patient receipt of an antibiotic with in vitro activity versus
the identified organism, time to de-escalation: switching from a
broad- to a narrow-spectrum antibiotic or discontinuation of one
or more antibiotics, time to escalation: switching from a narrow-
to a broad-spectrum antibiotic or initiation of one or more an-
tibiotics, as outlined in the Types of outcome measures section.
We will describe the study settings, number of participants, and
number of studies addressing each outcome.
We will assess the certainty of evidence using the GRADE ap-
proach (Guyatt 2011; GRADE 2014), and GRADEpro GDT
software (GRADEpro GDT 2015). We will rate each important
outcome as described by Balshem 2011.
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• High: we are very confident that the true effect lies close to
that of the estimate of the effect.
• Moderate: we are moderately confident in the effect
estimate; the true effect is likely to be close to the estimate of the
effect.
• Low: our confidence in the effect estimate is limited; the
true effect may be substantially different from the estimate of the
effect.
• Very low: we have very little confidence in the effect
estimate; the true effect is likely to be substantially different from
the estimate of effect.
RCTs start as high certainty of evidence but can be downgraded
if there are valid reasons within the following five categories: risk
of bias, imprecision, inconsistency, indirectness, and publication
bias (Balshem 2011).
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A P P E N D I C E S
Appendix 1. Included interventions
Molecular: matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MS) based resistance test (MALDI-TOFMS);
fluorescence in situ hybridization with peptide nucleic acid (PNA-FISH); multiplex polymerase chain reaction (PCR); FilmArray;
GenoType blood culture; GeneXpert MRSA Cepheid; Verigene Nanosphere; BD Gene Ohm StaphSR Becton Dickinson; BDMax
Staph; Eazyplex; AID; LightMix; Check-Direct CPE; MyCycler; Sepsis FlowChip; CheckPoints; Prove-it Sepsis; B-lacta test.
Phenotypic: Accelerate Pheno; Alfred 60/AST; forward laser light scatter; qMAC-sRAST; ViteK2.
Appendix 2. MEDLINE (PubMed) search strategy
Search Query
#1 Search ”bloodstream infection*“ or ”blood-stream infection*“ Field: Title/Abstract
#2 Search ”Bacteremia“[Mesh]
#3 Search bacteremia or bacteraemia Field: Title/Abstract
#4 Search ”blood culture*“ Field: Title/Abstract
#5 Search sepsis Field: Title/Abstract
#6 Search Sepsis [Mesh]
#7 Search ((#6) or (#5) OR (#4) OR #3) or #2) or #1)
#8 Search (Streptococci or “Streptococcus pneumoniae” or “Streptococcus agalactiae” or “Streptococcus pyogenes” or “Strep-
tococcus viridans” or Staphylococci or “Staphylococcus aureus” or MSSA or MRSA or “Staphylococcus epidermidis” or
“Staphylococcus saprophyticus” or “Coagulase negative Staphylococci” or Enterococci or “Enterococcus faecium” or “Ente-
rococcus faecalis” or Listeria or “Listeria monocytogenes”or Clostridium or Fusobacterium or Peptostreptococcus or Bacillus
or Haemophilus or “Haemophilus influenzae” or Brucella or Enterobacteriaceae or “Escherichia coli” or Klebsiella or Pro-
teus or Enterobacter or Salmonella or Citrobacter or Pseudomonas or “Pseudomona aeruginosa” or Serratia or Acinetobac-
ter or Stenotrophomonas or Legionella or Helicobacter or Moraxella or Neisseria or “Neisseria meningitidis”or “Neisseria
gonorrhoeae” or “Gram-negative” or “Gram-positive”) AND blood* Field: Title/Abstract
#9 Search (#7) OR #8)
#10 Search ”antimicrobial susceptibility test“ or “antimicrobial susceptibility testing” or “antibiotic susceptibility testing” or
“susceptibility testing” Field: Title/Abstract
#11 Search ”rapid“ Field: Title/Abstract
#12 Search ”maldi tof“ OR ”PNA-FISH“ Field: Title/Abstract
#13 Search PCR Field: Title/Abstract OR ”Polymerase Chain Reaction“[Mesh]
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(Continued)
#14 Search FilmArray or Microarray or “molecular test” or “GenoType Blood Culture” or GeneXpert or Cepheid or “Verigene
Nanosphere” Field: Title/ Abstract
#15 Search “BD Gene Ohm” or “BDMax Staph” or Eazyplex or LightMixor “Check-Direct CPE” Field: Title/Abstract
#16 Search FlowChip or “Prove-it ” or “Betalacta test” Field:Title/Abstract
#17 Search (“Pheno Accelerate” or “Alfred 60 AST” or “Light scattering” or “BacterioScan” or “qMAC-sRAST” or “Vitek2”)
Field: Title/Abstract
#18 Search “antimicrobial stewardship” or “antimicrobial prescription” Field: Title/Abstract
#19 Search ((((((#18 OR (17 ) OR #16) OR #15) OR #14) OR #13) OR #12) OR #11) OR #10) OR #9
#20 Search #9 AND #19
#11 Search“Randomized Controlled Trial” [Publication Type] OR “Controlled Clinical Trial” [Publication Type]
#22 Search (random* or placebo or single-blind* or double-blind*) Field:Title/Abstract
#23 Search impact or “clinical impact” or outcomes or clinical or “clinical outcomes” or effect Field: Title/Abstract
#24 Search evaluation or performance AND (impact* or outcome*) Field: Title/Abstract
#25 Search ((#24) OR (#23) OR #22) OR #21
#26 Search #20 AND #25
This is the preliminary search strategy for MEDLINE (PubMed). It will be adapted for other electronic databases. We will report all
search strategies in full in the final version of the review.
Appendix 3. Definitions
• Rapid susceptibility technique: an in vitro laboratory test used to determine if an antimicrobial agent will be active in inhibiting
the growth of an organism, performed directly from a positive blood culture bottle, producing results in < 8 hours or same working
day.
• Phenotypic susceptibility test: the basis of phenotypic method is the minimum inhibitory concentration (MIC). Clinical MIC
breakpoints determine whether the organism is categorized as susceptible, intermediate or resistant.
• Molecular or genotypic susceptibility test: a diagnostic test that analyzes the presence or absence of resistant genes in bacteria.
• Appropriate antimicrobial therapy: antimicrobial treatment directed specifically to a micro-organism based on in vitro
susceptibility test results.
• Time-to-result: the time that it takes to perform and report a laboratory susceptibility test result from the time that the sample is
received in the laboratory.
• Bloodstream infection (BSI) or bacteraemia: positive blood culture result with systemic manifestations of infection.
9Rapid versus standard antibiotic susceptibility testing for treating bloodstream infections (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
Vanesa Anton (VA) and Paul Hine (PH) wrote the first draft of the protocol. Sanjeev Krishna (SK), Marty Richardson (MR), and
Timothy Planche (TP) commented and revised the protocol. All review authors take responsibility for the final version of the protocol.
D E C L A R A T I O N S O F I N T E R E S T
VA has no known conflicts of interest.
PH was previously employed full-time by Cochrane Infectious Diseases Group (CIDG), and currently works full-time within the UK
National Health Service (NHS). He received a Registration Scholarship to attend the 23rd Annual British HIV Association Conference
2017 from ViiV healthcare. ViiV had no involvement in the selection of recipients of the scholarship. In 2018, he attended a CPD-
certified clinical research training programme organized and funded by Gilead Sciences Europe Ltd. To the best of his knowledge,
neither financial or non-financial conflicts of interests have influenced the current submitted work.
SK is a scientific advisor and shareholder in QuantuMDx, a company that is developing rapid diagnostic tests for several infections and
is a scientific advisor to Foundation for Innovative New Diagnostics (FIND). The opinions in this review are personal opinions and
do not represent views of either organization.
MR has no known conflicts of interest.
TP is the clinical lead of a NHS diagnostic microbiology laboratory at South West London Pathology. He is on advisory boards for
Roche, Pfizer, and Singulex for diagnostics.
S O U R C E S O F S U P P O R T
Internal sources
• Liverpool School of Tropical Medicine, UK.
External sources
• Department for International Development (DFID), UK, UK.
Project number 300342-104
• Collaboration for Leadership in Applied Health Research and Care (CLAHRC), UK.
10Rapid versus standard antibiotic susceptibility testing for treating bloodstream infections (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
